Group items matching

in title, tags, annotations or url

The Department of Health and Social Care has updated the list of community pharmacies eligible for the Pharmacy Access Scheme (PhAS) and approved 43 cases out of 63 applications, bringing the the total number of eligible pharmacies in England to 1,445. Earlier this year, NHS England and NHS Improvement (NHSE&I) invited community pharmacy contractors to apply for a review if they believed there were any inaccuracies in relation to pharmacy premises addresses or unforeseen circumstances affecting access, such as a permanent roadblock. Submitted applications were reviewed by the relevant NHSE&I regional pharmacy contract team, and determined by the relevant pharmaceutical services regulations committees (PSRC). Due to the workload pressures seen over winter, the review deadline was extended, giving contractors applying for a review two full months to complete their applications. This also pushed back the announcement of the outcome of the review, but where an application has been successful, PhAS payments will be backdated to the start of the scheme.

Pharmacy contractors will no longer need to print and submit a paper copy of their completed FP34C declaration made through the Manage Your Service (MYS) portal when submitting their paper prescription bundle to the NHS Business Services Authority (NHSBSA), said the Pharmaceutical Services Negotiating Committee (PSNC). Instead, from August 2022 (for July 2022 prescriptions), NHSBSA will post out a paper Account Identifier Document along with the red separators and pharmacy address labels each month. "The Account Identifier Document should be placed alongside the paper prescription bundle before it is dispatched for payment to the relevant pricing division of NHSBSA," said PSNC. With the help of Account Identifier Document, NHSBSA will be able to easily identify the pharmacy that has submitted the prescription bundle, which will help to speed up prescription processing. "If the Account Identifier Document is lost or misplaced, contractors will still be able to download and print another copy from MYS. The July 2022 Drug Tariff will be updated to reflect this change."

LloydsPharmacy has offered three per cent increase in base pay backdated to 1 April for its store pharmacists, the union of Pharmacists' Defence Association (PDAU) who represented them has announced. "We are pleased to announce that following a consultation of its members, the PDAU has informed the company that agreement can be reached on the company's latest offer, made in July 2022," said the PDAU. The offer made by the company also includes introduction of an overtime rate of 1.5 times basic pay for each hour worked after contracted hours. This will run for a trial period and be reviewed as part of the next pay round. "All pharmacists will receive an initial £1,000 payment under the proposed LTIP scheme, paid in April 2024. This will be to all in the bargaining unit and will not be dependent on meeting any criteria such as targets," said PDAU.

The Department of Health and Social Care (DHSC) has introduced new arrangements for the application of discount deduction to community pharmacy payments which will be implemented in six financial quarters beginning in October 2022 and concluding in January 2024. Under the new discount deduction system, the current single scale will be split into three groups: one each for generic medicines, branded medicines, and appliances. Separate fixed deduction rates have been determined for each group. This will provide all pharmacies the same rates of deduction applied to their reimbursement for the three different groups, regardless of the total value of that reimbursement. Fin McCaul, PSNC member and independent community pharmacy contractor, said: "The discount deduction scale has been a point of contention for contractors for many years, and PSNC has long been pushing to remedy this. "The incoming changes are designed to both improve equity of access to margin and manage the distortions presented by branded medicines, which just don't have the same level of discount available as generics.

Following the UK government's new pay offer to NHS consultants, the Royal College of Nursing (RCN) wrote to the Health Secretary Victoria Atkins calling for fresh negotiations about nursing pay in England last week. However, the Department of Health and Social Care (DHSC) has rejected their demand, stating that there is no basis to reopen talks as the pay deal was accepted by the NHS Staff Council. In the previous pay deal, nurses were given a one-off payment between £1,655 and £3,789 for 2022/23, and a 5 per cent consolidated pay increase for the 2023/24 financial year. Nursingnotes quoted a DHSC spokesperson as saying: "We hugely value the hard work of NHS nurses and that is why we provided a 5 per cent pay rise. "We also provided two significant non-consolidated awards, which for nurses at the top of Band 5 was over £2,000, equivalent to an extra 6.1 per cent of their basic pay.

The Pharmaceutical Services Negotiating Committee has announced that the Department of Health and Social Care (DHSC) has granted further price concessions for the month of December 2021. A price concession only applies for the month in which it is granted. No additional prescription endorsement are required as the new price is automatically applied by the NHS BSA to all items submitted for payment in the same month for which a price concession is granted. Contractors can find information and learn about the process involved on PSNC's website.

Britain's GlaxoSmithKline will receive $1.25 billion (about £921 million) from Gilead Sciences as part of a settlement between its HIV medicines unit and the US-based drugmaker, ending a long-drawn patent dispute. The settlement, announced by GSK on Tuesday (February 1), relates to Gilead's antiretroviral drug Biktarvy, a medicine used to check the AIDS-causing virus, which GSK said in 2018 infringed on its unit ViiV Healthcare's dolutegravir and other similar compounds. HIV medicines developed by ViiV, in which Pfizer and Japan's Shionogi also hold small stakes, are a major part of GSK's plan to support its lagging pharmaceuticals business as it readies to spin off its consumer healthcare arm. The payment is expected to be made in the first quarter this year, London-listed GSK said. Gilead will also pay a 3 per cent royalty until 2027 on sales of Biktarvy and on future US sales of any product containing its main component.

The government has announced a freeze to the NHS prescription charges, first time in 12 years, to help people ease with the cost of living and ensure prescription medication remains accessible. Charges for prescriptions will remain at £9.35 for a single charge or £30.25 for a 3-month prescription prepayment certificate (PPC), the Department of Health and Social Care (DHSC) said, adding that the measure will help save £17 million. The 12-month PPCs will remain at £108.10 and can be paid for in instalments, meaning people can get all the medicines they need for just over £2 a week, it added. The NHS low income scheme will also help with prescription payments, with free prescriptions for eligible people in certain groups such as pensioners, students, and those who receive state benefits or live in care homes. "The rise in the cost of living has been unavoidable as we face global challenges and the repercussions of Putin's illegal war in Ukraine. While we cannot completely prevent these rises, where we can help, we absolutely will," Health and Social Care Secretary Sajid Javid said. "This is why I am freezing prescription charges to help ease some of these pressures and put money back in people's pockets."

The Department of Health and Social Care (DHSC) has introduced a new prescription pre-payment certificate (PPC) for Hormone Replacement Therapy (HRT) which is said to benefit around 400,000 women who suffer from negative symptoms of the menopause in England. PPC will be rolled-out from 1 April and it reduce the HRT costs to less than £20 a year. Women prescribed HRT - the main treatment for menopause symptoms - will have access to a new scheme enabling access to a year's worth of menopause prescription items for the cost of two single prescription charges (currently £18.70). As part of commitments to reduce the cost of HRT for menopausal women, the prescription PPC will be valid for 12 months. It can be used against a list of HRT prescription items, and a patient can use this against an unlimited number of HRT items, such as patches, tablets and topical preparations. There will be no limit to how many times the certificate can be used while it is valid. "The introduction of the certificate delivers one of our year one priorities for the Women's Health Strategy for England. Published last summer, the strategy sets out an ambitious new agenda for improving the health and wellbeing of women and girls and to improve how the health and care system listens to women. Menopause was announced as a priority area within the strategy," said DHSC.

The Pharmaceutical Services Negotiating Committee (PSNC) has urged pharmacy contractors to use Manage Your Service (MYS) portal only for all monthly FP34C submissions. To secure access to earlier advance payments on 11 April 2022, the committee has advised pharmacy contractors to submit their claims for NHS pharmaceutical services delivered in March 2022 no later than 5 April 2022. PSNC said: "The Manage Your Service (MYS) portal is now the ONLY route available to contractors for all monthly FP34C submissions. From March 2022, contractors will no longer receive the paper FP34C submission document through the post. However, the NHSBSA will continue to post out red separators for contractors to submit relevant forms each month.

Swiss generic drugmaker Sandoz said on Thursday that it would pay $265 million (£209m) to settle a pricing antitrust case in the US. Under the agreement, Sandoz is resolving all damages claims without admitting to any wrongdoing in the case brought in the US state of Pennsylvania. "Under the terms of the agreement, Sandoz US will pay $265 million in exchange for a full release of all claims asserted against it in the direct purchaser class action by the settlement class members," the company said in a statement, adding that the payment would be incorporated into 2023 results. Sandoz became an independent company in October 2023, following the spinoff from Novartis. "As a new public company, this settlement underscores the Sandoz commitment to integrity and sound governance, and is an encouraging step toward putting allegations of legacy conduct behind us", it said in its statement.

A drug dealer who was operating as an "unlicensed chemist" and selling prescription drugs online has been jailed for six years, according to Essex Police. The convict, identified as 49-year-old Christopher Depp, aka David Jones, was supplying a range of drugs from his home to "vulnerable people" using the postal service, local police revealed on Friday (February 16). Police conducted a search operation at his address in Wood Street, Chelmsford, in July last year and found more than 50,000 pills and tablets of varying types, stashed in toolboxes and spaces around the property. To process the large-scale sale and shipping of controlled drugs across the UK, Depp had set up a room in his property as an office space. He promoted the sale of medications through various social media platforms and messaging applications, and accepted payment from his large customer base using "fraudulently obtained" bank accounts.

The Department of Health and Social Care (DHSC) has redetermined the December 2023 concessionary prices for four medicines following requests made by Community Pharmacy England (CPE) on behalf of community pharmacy owners. For Ezetimibe 10mg tablets (pack size 28), the price has been fixed at £17.78, up from £9.44. Other drugs included in the list are Aripiprazole 5mg (£8.52), Digoxin 125microgram (£3.70) and Digoxin 250micrgram (£3.70) tablets. Contractors would be reimbursed at the new prices only for prescriptions submitted for payment for the dispensing month of December 2023. CPE said they are still working with DHSC to agree price concessions for January. Check the final the December 2023 price concessionary here. Additionally, DHSC on Friday confirmed that there's now sufficient stock of Clarithromycin 125mg/5ml oral suspension to meet normal demand, and the Serious Shortage Protocol (SSP), SSP053 for the antibiotic expires on 12 January 2024.

NHS England has agreed to offer an additional payment of £2.50 per jab if pharmacies would be willing to extend the duration of their COVID-19 vaccination contract until 31st August 2024. Pharmacies currently providing the autumn vaccination are asked to let their local commissioner know, by 22nd February 2024, if they can provide cover for a potential Spring booster programme, if the Joint Committee on Vaccination and Immunisation (JCVI) advises in their guidance expected to be published soon. NHS figures showed that more than 3,500 community pharmacies signed the contract to deliver COVID-19 vaccinations between 1 September 2023 and 31 March 2024, as part of the autumn booster programme. The health service is hoping that most of these pharmacies will be able to continue to support the Spring campaign, which will run from 1 April 2024 to 31st August 2024, to help protect the nation's most vulnerable populations. For the Spring campaign only, pharmacies would be offered an extra £2.50 per jab in addition to the existing item of service fee of £7.54, NHS England said.

The Department of Health and Social Care (DHSC) has revised concession prices for four products and confirmed three further price concessions for May 2024. This announcement comes in response to representations made by Community Pharmacy England (CPE) on behalf of community pharmacy owners Concession prices have been redetermined for Ezetimibe 10mg tablets, Quetiapine 100mg tablets, Quetiapine 150mg tablets and Quetiapine 200mg tablets. Here are the newly granted concessions: Nicorandil 10mg tablets (60 tablets): £5.05 Nicorandil 20mg tablets (60 tablets): £9.30 Pregabalin 75mg capsules (56 capsules): £1.54 The revised prices will be applicable to prescriptions submitted for payment during the dispensing month of May 2024, and do not apply to June 2024 prescriptions, the CPE noted.

The founders envisioned the name, P3Care, after many brainstorming sessions and practically evaluating the stakeholders in the healthcare industry. After a critical analysis, they concluded that three entities are under the direct influence of the healthcare sector - Patients, Providers, and Payers. You cannot exclude any one of them if you look at the process, starting with the patients visiting the doctors and ending up with the doctors getting paid for their services.

We see hospitals and practices, in general, are equipped with the latest certified EHR systems aiding a new-age healthcare system to evolve, sustain, and respond with improved outcomes. Medical billing services and the doctors have to follow HIPAA rules, and physicians must demonstrate meaningful use to avoid negative payment adjustments. All of this means we are transitioning to the value-based system moving towards improvement.

MIPS 2019 performance year is about to end. Only a little time is left until eligible clinicians can report for MIPS healthcare. MIPS put forwards the opportunity to get incentives and bonuses aside from the regular payment model.

Currently, the healthcare system is going through a critical phase that involves shifting paradigms, from the volume-based model to the value-based reimbursement system. All of this is intended to minimize healthcare costs and raise the quality of care.

Small Medical Practices! P3Care has been doing well as MIPS Qualified Registry for four years now. During this time, we come up with many little tricks to achieve a minimum performance threshold to be safe from the penalty. Read the article below to know how small practices can avoid the negative payment adjustment in MIPS 2019 reporting.